Olema Pharmaceuticals, Inc. 10-Q

Item 5. Other Information. In November 2021, we were alerted to falsified information circulating on social media relating to our planned poster presentation for the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250 at the San Antonio Breast Cancer Symposium. The falsified poster image was not released or authorized by us. In December 2021, a Special Committee of our Board of Directors, with assistance of outside counsel, initiated an investigation into the circumstances regarding these matters. The Special Committee’s outside counsel contacted the SEC to inform of the Special Committee’s investigation. 99 Table of Contents Item 6. Exhibits. Furnish the exhibits required by Item 601 of Regulation S-K (§ 229.601 of this chapter). ​ ​ ​ ​ ​ ​ ​ ​ Incorporated by Reference Exhibit Number Description Schedule Form File Number Exhibit Filing Date 3.1 Amended and Restated Certificate of Incorporation 8-K 001-39712 3.1 11/23/2020 3.2 Amended and Restated Bylaws 8-K 001-39712 3.2 11/23/2020 10.1 Olema Pharmaceuticals, Inc. 2022 Inducement Plan 10-K 001-39712 10.17 2/28/2022 10.2 Form of Stock Option Agreement and Option Grant Notice under the Inducement Plan. 10-K 001-39712 10.18 2/28/2022 10.3 Offer Letter by and between the Registrant and Naseem Zojwalla, dated December 15, 2021. 10-K 001-39712 10.19 2/28/2022 31.1* Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2* Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. ​ ​ ​ ​ 32.1* Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS* XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL Document ​ ​ ​ ​ 101.SCH* XBRL Taxonomy Extension Schema Document ​ ​ ​ ​ 101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document ​ ​ ​ ​ 101.DEF* XBRL Taxonomy Extension Definition Linkbase Document ​ ​ ​ ​ 101.LAB* XBRL Taxonomy Extension Label Linkbase Document ​ ​ ​ ​ 101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document ​ ​ ​ ​ 104 Cover Page Interactive Data File – The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document ​ ​ ​ ​ ​ ​ * Filed herewith. ​ 100 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Olema Pharmaceuticals, Inc. Date: May 9, 2022 By: /s/ Sean Bohen, M.D., Ph.D. ​ ​ Sean Bohen, M.D., Ph.D. President and Chief Executive Officer ( Principal Executive Officer ) Olema Pharmaceuticals, Inc. Date: May 9, 2022 By: /s/ Shane Kovacs ​ ​ Shane Kovacs Chief Operating and Financial Officer ( Principal Financial Officer and Principal Accounting Officer ) ​ ​ ​ 101